115 related articles for article (PubMed ID: 7849230)
1. A pharmacokinetic evaluation of HIV protease inhibitors, cyclic ureas, in rats and dogs.
Wong YN; Burcham DL; Saxton PL; Erickson-Viitanen S; Grubb MF; Quon CY; Huang SM
Biopharm Drug Dispos; 1994 Oct; 15(7):535-44. PubMed ID: 7849230
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of HIV protease inhibitor DMP 323 in rats and dogs.
Grubb MF; Wong YN; Burcham DL; Saxton PL; Quon CY; Huang SM
Drug Metab Dispos; 1994; 22(5):709-12. PubMed ID: 7835221
[TBL] [Abstract][Full Text] [Related]
3. Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
Rodgers JD; Lam PY; Johnson BL; Wang H; Li R; Ru Y; Ko SS; Seitz SP; Trainor GL; Anderson PS; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Wright MR; Chang CH; Erickson-Viitanen S
Chem Biol; 1998 Oct; 5(10):597-608. PubMed ID: 9818151
[TBL] [Abstract][Full Text] [Related]
4. Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450.
Hodge CN; Aldrich PE; Bacheler LT; Chang CH; Eyermann CJ; Garber S; Grubb M; Jackson DA; Jadhav PK; Korant B; Lam PY; Maurin MB; Meek JL; Otto MJ; Rayner MM; Reid C; Sharpe TR; Shum L; Winslow DL; Erickson-Viitanen S
Chem Biol; 1996 Apr; 3(4):301-14. PubMed ID: 8807858
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease.
Shetty BV; Kosa MB; Khalil DA; Webber S
Antimicrob Agents Chemother; 1996 Jan; 40(1):110-4. PubMed ID: 8787890
[TBL] [Abstract][Full Text] [Related]
6. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors.
Lam PY; Jadhav PK; Eyermann CJ; Hodge CN; Ru Y; Bacheler LT; Meek JL; Otto MJ; Rayner MM; Wong YN
Science; 1994 Jan; 263(5145):380-4. PubMed ID: 8278812
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
Kaltenbach RF; Patel M; Waltermire RE; Harris GD; Stone BR; Klabe RM; Garber S; Bacheler LT; Cordova BC; Logue K; Wright MR; Erickson-Viitanen S; Trainor GL
Bioorg Med Chem Lett; 2003 Feb; 13(4):605-8. PubMed ID: 12639540
[TBL] [Abstract][Full Text] [Related]
8. Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
De Lucca GV; Kim UT; Liang J; Cordova B; Klabe RM; Garber S; Bacheler LT; Lam GN; Wright MR; Logue KA; Erickson-Viitanen S; Ko SS; Trainor GL
J Med Chem; 1998 Jun; 41(13):2411-23. PubMed ID: 9632373
[TBL] [Abstract][Full Text] [Related]
9. HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.
Wilkerson WW; Akamike E; Cheatham WW; Hollis AY; Collins RD; DeLucca I; Lam PY; Ru Y
J Med Chem; 1996 Oct; 39(21):4299-312. PubMed ID: 8863807
[TBL] [Abstract][Full Text] [Related]
10. SDZ PRI 053, an orally bioavailable human immunodeficiency virus type 1 proteinase inhibitor containing the 2-aminobenzylstatine moiety.
Billich A; Fricker G; Müller I; Donatsch P; Ettmayer P; Gstach H; Lehr P; Peichl P; Scholz D; Rosenwirth B
Antimicrob Agents Chemother; 1995 Jul; 39(7):1406-13. PubMed ID: 7492076
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study of a tripeptide HIV-1 protease inhibitor, KNI-174, in rats after intravenous and intraduodenal administrations.
Kiriyama A; Mimoto T; Kiso Y; Takada K
Biopharm Drug Dispos; 1993 Apr; 14(3):199-207. PubMed ID: 8490108
[TBL] [Abstract][Full Text] [Related]
12. Novel azacyclic ureas that are potent inhibitors of HIV-1 protease.
Sham HL; Zhao C; Marsh KC; Betebenner DA; Lin S; Rosenbrook W; Herrin T; Li L; Madigan D; Vasavanonda S; Molla A; Saldivar A; McDonald E; Wideburg NE; Kempf D; Norbeck DW; Plattner JJ
Biochem Biophys Res Commun; 1996 Aug; 225(2):436-40. PubMed ID: 8753780
[TBL] [Abstract][Full Text] [Related]
13. Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
Han Q; Chang CH; Li R; Ru Y; Jadhav PK; Lam PY
J Med Chem; 1998 Jun; 41(12):2019-28. PubMed ID: 9622543
[TBL] [Abstract][Full Text] [Related]
14. Potent inhibitors of the HIV-1 protease with good oral bioavailabilities.
Sham HL; Zhao C; Marsh KC; Betebenner DA; Lin S; McDonald E; Vasavanonda S; Wideburg N; Saldivar A; Robins T
Biochem Biophys Res Commun; 1995 Jun; 211(1):159-65. PubMed ID: 7779082
[TBL] [Abstract][Full Text] [Related]
15. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.
Kempf DJ; Marsh KC; Denissen JF; McDonald E; Vasavanonda S; Flentge CA; Green BE; Fino L; Park CH; Kong XP
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2484-8. PubMed ID: 7708670
[TBL] [Abstract][Full Text] [Related]
16. SC-52151, a novel inhibitor of the human immunodeficiency virus protease.
Bryant M; Getman D; Smidt M; Marr J; Clare M; Dillard R; Lansky D; DeCrescenzo G; Heintz R; Houseman K
Antimicrob Agents Chemother; 1995 Oct; 39(10):2229-34. PubMed ID: 8619573
[TBL] [Abstract][Full Text] [Related]
17. Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole.
Yuan JH; Stolzenbach JC; Salamon CM; Snook SS; Schoenhard GL
Xenobiotica; 1997 May; 27(5):489-97. PubMed ID: 9179989
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel benzothiazolesulfonamides as potent inhibitors of HIV-1 protease.
Nagarajan SR; De Crescenzo GA; Getman DP; Lu HF; Sikorski JA; Walker JL; McDonald JJ; Houseman KA; Kocan GP; Kishore N; Mehta PP; Funkes-Shippy CL; Blystone L
Bioorg Med Chem; 2003 Nov; 11(22):4769-77. PubMed ID: 14556792
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship of HIV-1 protease inhibitors containing AHPBA. Part III: Modification of P2 site.
Takashiro E; Watanabe T; Nitta T; Kasuya A; Miyamoto S; Ozawa Y; Yagi R; Nishigaki T; Shibayama T; Nakagawa A; Iwamoto A; Yabe Y
Bioorg Med Chem; 1998 May; 6(5):595-604. PubMed ID: 9629473
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics and oral bioavailability studies of columbianetin in rats after oral and intravenous administration.
Luo Q; Wang CP; Li J; Ma WF; Bai Y; Ma L; Gao XM; Zhang BL; Chang YX
J Ethnopharmacol; 2013 Oct; 150(1):175-80. PubMed ID: 23994338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
